Market Overview

Hyperoxaluria| A Drug Pipeline Analysis Report 2018| Technavio

Share:

Technavio has announced their latest analysis report on drug pipeline
for hyperoxaluria.
The report includes a detailed analysis of the pipeline molecules under
investigation within the defined data collection period to treat
hyperoxaluria.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180803005363/en/

Technavio has published a new report on the drug development pipeline for hyperoxaluria, including a ...

Technavio has published a new report on the drug development pipeline for hyperoxaluria, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Hyperoxaluria: Market overview

Hyperoxaluria is a state of disordered metabolism characterized by an
increased urinary excretion of oxalate. The daily oxalate excretion in
healthy individuals ranges between 10 mg and 40 mg per 24 hours.
Concentrations exceeding 40-45 mg per 24 hours are considered as
clinical hyperoxaluria. Hyperoxaluria is of several types including
primary hyperoxaluria, oxalosis, enteric hyperoxaluria, hyperoxaluria
related to eating high-oxalate foods.

According to a senior market research analyst at Technavio, "The
worldwide prevalence of primary hyperoxaluria is estimated to affect one
in 58,000 individuals. One estimate places the prevalence of primary
hyperoxaluria type I at 1-3 cases per 1,000,000 people in the general
population, and the incidence at one case per 120,000 live births per
year in Europe. Hyperoxaluria is uncommon, though it can be found in
about 20% of individuals with kidney stones."

Hyperoxaluria: Segmentation analysis

This pipeline analysis report segments the hyperoxaluria market based on
therapies employed (monotherapy), RoA (oral and subcutaneous),
therapeutic modality (enzyme, SiRNA, and biological), targets (oxalate,
glycolate oxidase, LDHA gene, and hydroxyacid oxidase 1), MoA (oxalate
degraders, reduces hepatic glycolate oxidase, silences the LDHA gene,
and gene transfer), geographical segmentation (US, UK, Spain,
Netherlands, Germany, France, Jordan, Israel and Belgium) and
recruitment status (active, not recruiting, completed, and recruiting).
It provides an in-depth analysis of the prominent factors influencing
the market, including drivers, opportunities, trends, and
industry-specific challenges.

Based on therapeutic modality, around 50% of the molecules that are
being investigated for the treatment of hyperoxaluria are enzymes.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!